Drugs Affecting Blood and Blood Formation Practice Questions

Q: Caplacizumab is used for the treatment of which condition?

Acquired Thrombotic Thrombocytopenic Purpura (aTTP). **Explanation:** **Caplacizumab** is a novel, humanized **bivalent nanobody** (a single-variable-domain antibody fragment) specifically designed to target the A1 domain of **von Willebrand factor (vWF)**. 1. **Why Option A is correct:** Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is caused by a deficiency of the ADAMTS13 enzyme, leading to ultra-large vWF multimers. These multimers cause spontaneous platelet aggregation and microvascular thrombosis. Caplacizumab **inhibits the interaction between vWF and the platelet glycoprotein Ib-IX-V receptor**, thereby preventing the formation of microthrombi and the subsequent consumption of platelets. It is used as an adjunct to plasma exchange and immunosuppressive therapy. 2. **Why other options are incorrect:** * **Plaque Psoriasis:** Treated with biologics targeting IL-17 (Secukinumab), IL-23 (Ustekinumab), or TNF-alpha (Adalimumab). * **Breast Cancer:** Common targeted therapies include Trastuzumab (anti-HER2) or Palbociclib (CDK4/6 inhibitor). * **Bladder Cancer:** Often treated with Pembrolizumab (PD-1 inhibitor) or Enfortumab vedotin (Nectin-4 inhibitor). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Anti-vWF nanobody (prevents platelet adhesion). * **Indication:** First-line treatment for **aTTP** to achieve faster platelet normalization and reduce recurrence. * **Route:** Administered intravenously (loading dose) followed by subcutaneous injections. * **Adverse Effect:** Increased risk of **bleeding** (epistaxis, gingival bleeding) due to its mechanism of preventing platelet-vWF binding.

Q: Which of the following is an antifibrinolytic drug?

Tranexamic acid. **Explanation** The correct answer is **D. Tranexamic acid.** **1. Why Tranexamic Acid is Correct:** Tranexamic acid is a synthetic derivative of the amino acid lysine. It acts as an **antifibrinolytic** by competitively inhibiting the activation of plasminogen to plasmin. It binds to the lysine-binding sites on plasminogen molecules, preventing them from binding to fibrin. This stabilizes the fibrin clot and prevents its degradation (fibrinolysis). It is clinically used to reduce bleeding in conditions like menorrhagia, post-prostatectomy, and trauma (CRASH-2 trial). **2. Why Other Options are Incorrect:** * **A. Tenecteplase:** This is a third-generation **thrombolytic** (fibrinolytic) agent. It is a genetically engineered variant of tissue plasminogen activator (t-PA) with a longer half-life and higher fibrin specificity, used in the management of acute myocardial infarction. * **B. Heparin:** This is an **anticoagulant**. It acts by activating Antithrombin III, which then inactivates Thrombin (Factor IIa) and Factor Xa. It prevents the *formation* of a clot but does not dissolve existing clots or inhibit fibrinolysis. * **C. Urokinase:** This is a **thrombolytic** enzyme produced naturally by the kidneys. It directly converts plasminogen to plasmin, thereby promoting the breakdown of fibrin clots. **3. High-Yield NEET-PG Pearls:** * **Epsilon-aminocaproic acid (EACA)** is another lysine analogue antifibrinolytic similar to Tranexamic acid. * **Aprotinin** is a direct plasmin inhibitor (also inhibits kallikrein) used to reduce blood loss during cardiac surgery. * **Side Effect:** A rare but high-yield side effect of Tranexamic acid is **color vision disturbances** (chromatopsia). * **Antidote:** Tranexamic acid can be used as an "antidote" for bleeding caused by thrombolytic overdose.

Q: Which of the following is a Protein C analogue?

Drotrecogin alfa. **Explanation:** **Correct Answer: B. Drotrecogin alfa** Drotrecogin alfa is a **recombinant form of human Activated Protein C (APC)**. In the body, Protein C is a natural anticoagulant that is activated by the thrombin-thrombomodulin complex. Once activated, it inactivates Factors Va and VIIIa, thereby limiting thrombin generation. Additionally, it possesses anti-inflammatory and profibrinolytic properties. It was historically used in the management of severe sepsis with multi-organ failure, though its clinical use has significantly declined due to concerns regarding efficacy and bleeding risks. **Analysis of Incorrect Options:** * **A. Eltrombopag:** This is an orally active **Thrombopoietin (TPO) receptor agonist**. It stimulates the proliferation and differentiation of megakaryocytes to increase platelet counts. It is used in Chronic ITP and Aplastic Anemia. * **C. Andexanet alfa:** This is a recombinant modified human **Factor Xa decoy protein**. It acts as a specific **reversal agent (antidote)** for Factor Xa inhibitors like Rivaroxaban and Apixaban. * **D. Idarucizumab:** This is a humanized monoclonal antibody fragment (Fab) that acts as a specific **reversal agent (antidote) for Dabigatran** (a direct thrombin inhibitor). **High-Yield NEET-PG Pearls:** * **Protein S** acts as a cofactor for Protein C; deficiency of either leads to a hypercoagulable state (thrombophilia). * **Warfarin-induced skin necrosis** occurs due to a rapid decline in Protein C levels (which has a short half-life) before the depletion of clotting factors. * **Romiplostim** is another TPO receptor agonist but is administered subcutaneously (unlike Eltrombopag).

Q: What is the formula for parenteral iron therapy?

4.4 x body weight (kg) x Hb deficit (g/dL). The correct formula for calculating the total dose of parenteral iron is based on the **Ganzoni Equation**. This formula ensures that the patient receives enough iron to restore hemoglobin to normal levels and replenish depleted iron stores. ### **Explanation of the Correct Answer** **Option A (4.4 x body weight x Hb deficit)** is the correct simplified version of the Ganzoni Equation. * **The Logic:** To raise hemoglobin (Hb) by 1 g/dL, approximately 150 mg of iron is needed in an average adult. When factored by body weight (kg) and the deficit (Target Hb - Actual Hb), the constant **2.4** is typically used if Hb is in g/dL. However, when accounting for **iron stores** (usually 500 mg for adults), the simplified clinical multiplier often cited in standard pharmacology textbooks (like KD Tripathi) for total replacement is **4.4**. * **Formula:** Total Iron Dose (mg) = 4.4 × Body weight (kg) × Hb deficit (g/dL). ### **Why Other Options are Incorrect** * **Options B, C, and D** (3.3, 2.2, 1.1) are mathematically incorrect. These multipliers would result in significant under-dosing, failing to provide enough elemental iron to both reach the target hemoglobin level and provide the necessary 500 mg buffer for storage (ferritin). ### **NEET-PG High-Yield Pearls** 1. **Indications for Parenteral Iron:** Oral iron intolerance (most common), malabsorption (Celiac disease), chronic kidney disease (CKD) on erythropoietin, or the need for rapid replenishment (e.g., late pregnancy). 2. **Iron Sucrose vs. Ferric Carboxymaltose:** Iron sucrose is given in divided doses, whereas Ferric Carboxymaltose can be given as a large single-dose infusion. 3. **Adverse Effects:** Anaphylaxis is a risk (highest with older High Molecular Weight Iron Dextran). Always monitor the patient for at least 30 minutes post-infusion. 4. **Target Hb:** Usually taken as 14 g/dL or 15 g/dL for calculation purposes.

Q: Which of the following is a complication of heparin?

All of the above. **Explanation:** Heparin is a rapid-acting parenteral anticoagulant that acts by activating Antithrombin III. While highly effective, it is associated with several significant adverse effects, making **"All of the above"** the correct choice. 1. **Bleeding (Option A):** This is the most common complication of heparin therapy. It occurs due to the excessive inhibition of factors Xa and IIa (Thrombin). The risk is increased in elderly patients and those with renal failure. The specific antidote for heparin-induced bleeding is **Protamine Sulfate**. 2. **Thrombocytopenia (Option B):** Heparin-Induced Thrombocytopenia (HIT) is a serious immunologic reaction. **Type II HIT** is high-yield for exams; it is caused by IgG antibodies against the **Heparin-Platelet Factor 4 (PF4) complex**, leading to platelet activation and paradoxical thrombosis. 3. **Osteoporosis (Option C):** Long-term heparin use (typically >6 months, often during pregnancy) can lead to decreased bone density and spontaneous fractures. Heparin accelerates osteoclast activity and inhibits osteoblast formation. **Clinical Pearls for NEET-PG:** * **Monitoring:** Unfractionated Heparin (UFH) is monitored using **aPTT** (Target: 1.5–2.5 times the control). Low Molecular Weight Heparin (LMWH) usually doesn't require monitoring but can be checked using **Factor Xa assay**. * **Hyperkalemia:** Heparin can cause hypoaldosteronism by inhibiting the adrenal cortex, leading to potassium retention. * **Alopecia:** Transient hair loss is a rare, reversible side effect. * **LMWH vs. UFH:** LMWH (e.g., Enoxaparin) has a lower risk of HIT and osteoporosis compared to UFH.

Q: An 18-year-old previously healthy man is placed on intravenous heparin after having a pulmonary embolism (PE) after exploratory laparotomy for a small-bowel injury following a motor vehicle collision. Five days later, his platelet count is 90,000/mL and continues to fall over the next several days. The patient's serum is positive for antibodies to the heparin-platelet factor complexes. Which of the following is the most appropriate next management step?

Cessation of heparin and institution of lepirudin. ### Explanation **Concept: Heparin-Induced Thrombocytopenia (HIT) Type II** The patient presents with a classic case of **HIT Type II**, an immune-mediated reaction caused by IgG antibodies against the **Heparin-Platelet Factor 4 (PF4) complex**. This typically occurs 5–10 days after starting heparin, leading to platelet activation, consumption (thrombocytopenia), and a paradoxical high risk of arterial and venous thrombosis. **Why Option D is Correct:** The management of HIT requires the **immediate cessation of all heparin products** (including LMWH) and the initiation of a non-heparin anticoagulant. **Lepirudin** (a recombinant Hirudin) is a **Direct Thrombin Inhibitor (DTI)** that does not cross-react with HIT antibodies, making it a safe and effective alternative for systemic anticoagulation in these patients. **Why Other Options are Wrong:** * **Option A:** Stopping all anticoagulation is dangerous. HIT is a pro-thrombotic state; without alternative anticoagulation, the patient is at high risk for new or worsening PE/thrombosis. * **Option B:** Warfarin should **never** be used as monotherapy in acute HIT. It can cause a rapid drop in Protein C levels, leading to a hypercoagulable state and **venous limb gangrene**. Warfarin is only started after the platelet count has recovered to >150,000/mL. * **Option C:** LMWH (e.g., Enoxaparin) is contraindicated because it has high cross-reactivity (nearly 100%) with HIT antibodies and will worsen the condition. **NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Serotonin Release Assay (SRA). * **Screening Test:** ELISA for anti-PF4 antibodies (high sensitivity, low specificity). * **Alternative DTIs:** Argatroban (safe in renal failure) and Bivalirudin. * **Lepirudin Note:** It is renally excreted; monitor APTT closely. * **HIT Type I:** A non-immunologic, transient drop in platelets occurring within 48 hours; heparin can be continued.

Q: Heparin therapy should be monitored with intermittent estimation of which of the following?

Activated partial thromboplastin time (aPTT). The correct answer is **C. Activated partial thromboplastin time (aPTT)**. **Why aPTT is the correct choice:** Unfractionated Heparin (UFH) exerts its anticoagulant effect by binding to Antithrombin III, which subsequently inactivates Thrombin (Factor IIa) and Factor Xa [3]. The **aPTT** measures the integrity of the **intrinsic and common pathways** of the coagulation cascade. Since heparin significantly prolongs the clotting time of these pathways, aPTT is the standard laboratory test used to monitor its therapeutic efficacy and ensure safety [1]. The goal is typically to maintain the aPTT at 1.5 to 2.5 times the normal control value. **Why other options are incorrect:** * **Bleeding Time (A):** This test assesses platelet function and vascular integrity, not the coagulation cascade. While heparin affects clotting, it does not significantly alter the primary hemostatic plug formed by platelets. * **Prothrombin Time (B):** PT (and its derivative, INR) is used to monitor the **extrinsic pathway**, primarily for patients on **Warfarin** therapy. While very high doses of heparin can slightly affect PT, it is not sensitive or specific enough for monitoring heparin therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Low Molecular Weight Heparin (LMWH):** Unlike UFH, LMWH (e.g., Enoxaparin) does **not** require routine monitoring due to its predictable bioavailability. If monitoring is required (e.g., in renal failure or pregnancy), the **Anti-Factor Xa assay** is used [2]. * **Antidote:** The specific antidote for heparin overdose is **Protamine Sulfate** (1 mg neutralizes ~100 units of heparin). * **Side Effects:** Watch for **Heparin-Induced Thrombocytopenia (HIT)**; if it occurs, stop heparin immediately and switch to a direct thrombin inhibitor like Lepirudin or Argatroban.

Q: Apixaban is:

Direct Xa inhibitor. **Explanation:** **Apixaban** belongs to the class of drugs known as **Direct Oral Anticoagulants (DOACs)**. Its mechanism of action involves the direct, reversible, and highly selective inhibition of **Factor Xa** (both free and clot-bound). Factor Xa is a critical component of the "common pathway" in the coagulation cascade; by inhibiting it, Apixaban prevents the conversion of prothrombin to thrombin, thereby stopping fibrin clot formation. **Analysis of Options:** * **Option A (Antithrombin inhibitor):** This is incorrect. Drugs like Heparin actually work by *activating* Antithrombin III. Apixaban acts independently of antithrombin. * **Option C (Platelet activator):** This is incorrect. Apixaban is an anticoagulant, not a pro-coagulant. Furthermore, it affects the coagulation cascade, not platelet activation (which is the target of antiplatelet drugs like Aspirin or Clopidogrel). * **Option D (Clotting Factor XII):** This is incorrect. Factor XII (Hageman factor) is involved in the intrinsic pathway. There are currently no major clinical anticoagulants targeting Factor XII used in standard practice. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** Remember the **"xa"** in the name: Api**xa**ban, Rivaro**xa**ban, and Edo**xa**ban are all direct **Xa** inhibitors. * **Monitoring:** Unlike Warfarin, DOACs do not require routine PT/INR monitoring. * **Reversal Agent:** The specific antidote for Apixaban and Rivaroxaban is **Andexanet alfa**. * **Clinical Use:** Primarily used for stroke prevention in non-valvular atrial fibrillation and the treatment/prophylaxis of DVT and pulmonary embolism.

Question 1

Caplacizumab is used for the treatment of which condition?

Accepted Answer

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Answer

Plaque Psoriasis

Answer

Breast cancer

Answer

Bladder cancer

Question 2

Which of the following is an antifibrinolytic drug?

Accepted Answer

Tranexamic acid

Answer

Tenecteplase

Answer

Heparin

Answer

Urokinase

Question 3

Which of the following is a Protein C analogue?

Accepted Answer

Drotrecogin alfa

Answer

Eltrombopag

Answer

Andexanat alfa

Answer

Idarucizumab

Question 4

What is the formula for parenteral iron therapy?

Accepted Answer

4.4 x body weight (kg) x Hb deficit (g/dL)

Answer

3.3 x body weight (kg) x Hb deficit (g/dL)

Answer

2.2 x body weight (kg) x Hb deficit (g/dL)

Answer

1.1 x body weight (kg) x Hb deficit (g/dL)

Question 5

Which of the following is most useful in the treatment of Kostmann's Syndrome?

Accepted Answer

Filgrastim

Answer

Sargramostim

Answer

Aldesleukin

Answer

Oprelvekin

Question 6

Which of the following is a complication of heparin?

Accepted Answer

All of the above

Answer

Bleeding

Answer

Thrombocytopenia

Answer

Osteoporosis

Question 7

An 18-year-old previously healthy man is placed on intravenous heparin after having a pulmonary embolism (PE) after exploratory laparotomy for a small-bowel injury following a motor vehicle collision. Five days later, his platelet count is 90,000/mL and continues to fall over the next several days. The patient's serum is positive for antibodies to the heparin-platelet factor complexes. Which of the following is the most appropriate next management step?

Accepted Answer

Cessation of heparin and institution of lepirudin

Answer

Cessation of all anticoagulation therapy

Answer

Cessation of heparin and immediate institution of high-dose warfarin therapy

Answer

Cessation of heparin and institution of low-molecular-weight heparin

Question 8

Heparin therapy should be monitored with intermittent estimation of which of the following?

Accepted Answer

Activated partial thromboplastin time (aPTT)

Answer

Bleeding time

Answer

Prothrombin time

Answer

All of the above

Question 9

Which anticoagulant is only effective in vivo?

Accepted Answer

Coumarin

Answer

Heparin

Answer

EDTA

Answer

Sodium citrate

Question 10

Apixaban is:

Accepted Answer

Direct Xa inhibitor

Answer

Antithrombin inhibitor

Answer

Platelet activator

Answer

Clotting Factor XII

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?